A phase i trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 1, 2013, Pages 85-91

  Iqbal, Syma ^a   Lenz, Heinz Josef ^a   Gandara, David R ^b   Shibata, Stephen I ^c   Groshen, Susan ^a   Synold, Timothy W ^c   Newman, Edward M ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c City of Hope   (United States)

Author keywords

Docetaxel; Oxaliplatin; Oxaliplatin and Docetaxel; Phase I

Indexed keywords

DOCETAXEL; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER PAIN; CANCER SURVIVAL; CLINICAL ARTICLE; COLON CANCER; DEPRESSION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTRITIS; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERGLYCEMIA; HYPOPHOSPHATEMIA; INFECTION; LIVER CANCER; LIVER CELL CARCINOMA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; METABOLIC DISORDER; MINOR AFFECTIVE DISORDER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OPEN STUDY; OVARY CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RESTLESSNESS; SOLID TUMOR; SURVIVAL TIME; THYROID CANCER;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; SEVERITY OF ILLNESS INDEX; TAXOIDS; TUBULIN MODULATORS;

EID: 84879795373     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2171-4     Document Type: Article

References (9)

1. Cvitkovic E (1998) Ongoing and unsaid on oxaliplatin: the hope. Br J Cancer 77(Suppl 4):8-11
2. Silvestro L, Anal H, Sommer F (1990) Comparative effects of a new platinum analog (trans-1-diamine-cyclohexane oxalato-platinum: L-OHP) with CDDP on various cells: correlation with intracellular accumulation. Proc Anticancer Res, pp Abstract # 115
3. Pendyala L, Kidani Y, Perez R et al (1995) Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. Cancer Lett 97:177-184
4. Extra JM, Espie M, Calvo F et al (1990) Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25:299-303
5. Extra JM, Marty M, Brienza S et al (1998) Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 25:13-22
6. Synold TW, Takimoto CH, Doroshow JH et al (2007) Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res 13:3660-3666
7. Morgan RJ Jr, Doroshow JH, Synold T et al (2003) Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Clin Cancer Res 9:5896-5901
8. Kouroussis C, Agelaki S, Mavroudis D et al (2003) A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer. Anticancer Res 23:785-791
9. Kim KH, Park YS, Chang MH, Kim HS, Jun HJ, Uhm J, Yi SY, Lim do H, Ji SH, Park MJ, Lee J, Park SH, Park JO, Lim HY, Kang WK (2009) A phase I/II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer. Cancer Chemother Pharmacol 64(2):347-353. doi: 10.1007/s00280-008-0878-4